ISTANBUL, April 24, 2021 /PRNewswire/ -- Hair transplant in Turkey in general, is becoming a prevalent option to people worldwide. There are several reasons that explain why people want to get their hair implantation done at a hair transplant clinic in this country.The clinics in Turkey offer high-quality medical care, have the latest medical equipment, and, more importantly, have teams of highly experienced professionals. One of the clinics in this niche is the Sapphire Hair Clinic, and today, an introduction to this clinic and a new doctor that joined the staff will be presented.Sapphire Hair Transplant Clinic & Dr. Okan MorkoçSapphire Hair Clinic is a hair clinic in Turkey. The clinic specializes in Aesthetic Medicine and Cosmetology with a focus on hair restoration and transplantation. Sapphire Hair Clinic is a part of the Medical Park Hospitals Group network delivering "health for all" to people in 17 cities.To deliver unparalleled hair loss treatments to patients and improve what the clinic is offering, they focus on adopting new technologies, methods and expand their medical team of professionals. Dr. Okan Morkoç is the latest member of their hair transplant clinic team.
Dr. Okan Morkoç is not a new face on the medical scene in Turkey. He is a respected and established surgeon with years of medical practice in aesthetic and reconstructive surgery. He also has invaluable experience in hair transplant technique practices.Dr. Okan Morkoç graduated from the School of Medicine at Akdeniz University in Antalya and completed his residency at Haydarpasa Numune Training and Research Hospital at the Department of Plastic, Reconstructive, and Aesthetic Surgery.He worked as a Plastic, Reconstructive, and Aesthetic surgeon at Sivas Numune Hospital and Servergazi State Hospital before joining the Sapphire Hair Transplant Clinic team. There is no doubt that he is a highly-trained and experienced professional.Dr. Okan Morkoç and Sapphire Hair Clinic - A Perfect FitThe Sapphire Hair Transplant Clinic, specializes in hair restoration techniques. To deliver satisfactory results and medical care to their patients, they work with the latest technologies and proven hair transplantation techniques such as the Sapphire FUE method and DHI method, which stand for Follicular Unit Extraction and Direct Hair Implantation, respectively.
Sapphire Hair Clinic and Dr. Okan Morkoç are a good fit because he performs both FUE and DHI methods in the patient's best interest. His extensive experience and practical medical knowledge enable him to successfully carry out various hair restoration procedures efficiently utilizing the Sapphire Hair Clinic's resources.His knowledge and experience, paired with high-end technologies and surgical tools available at Sapphire Hair Clinic, generate the best possible results for patients. He can perform delicate hair transplant procedures with high accuracy and high graft survival rates.Dr. Okan Morkoç is proficient with using sapphire blades which are very thin and small. Using these microscopic sapphire blades enables him to cause minimal trauma to the scalp and tissue damage. This is why the patients that undergo the Sapphire FUE hair transplantation at their clinic go through a significantly shorter post-op period with no to minimal and barely visible scarring.Affordable Hair Transplant ProceduresIn the last couple of years, the clinic has experienced a large influx of international patients visiting hair clinics and having their procedures done in Turkey. One of the reasons is good medical care provided by clinics such as the Sapphire Hair Clinic.
Another reason is the affordability of hair transplantation procedures. Compared to hair transplant costs in Europe, the Sapphire Hair Clinic offers the same procedures but 70% cheaper on average.Modern Hair Transplantation Methods at Sapphire Hair ClinicSapphire Hair Clinic offers DHI, FUE, and Sapphire FUE hair transplantation methods.DHI or Direct Hair Implantation is one of the newest hair transplantation methods. It shares the same non-invasive follicular unit extraction method with FUE. However, it's different from FUE when it comes to how the hair is implanted. With DHI, there are no incisions. Instead, a patented tool implants hairs on the scalp. A special robotic system can do it too, so it is also called a robotic follicular unit extraction.FUE stands for Follicular Unit Extraction. It causes minimal trauma because a surgeon uses very small instruments to punch or extract follicles. Sapphire FUE hair transplantation offers an even better experience to patients because it encompasses using small sapphire blades for a minimal recovery process.
If one is looking for a professional in the field who can help restore one's natural hair look, one should consider Dr. Okan Morkoç. The clinic can be contacted at any time, and a free consultation with him is on the table. Related Imagesm-d-okan-morko.jpg M.D. Okan MorkoçPacking years of experience and a wealth of knowledge and expertise, Dr. Okan Morkoç landed his first job as a surgeon. View original content to download multimedia:https://www.prnewswire.com/news-releases/dr-okan-morkoc---the-new-face-of-the-sapphire-hair-transplant-clinic-in-turkey-301276259.htmlSOURCE Sapphire Hair Clinic
IOSCO - Implementation Monitoring Of The PFMI: Level 3 Assessment Of Financial Market Infrastructures’...
SUZHOU, China, April 24, 2021 /PRNewswire/ -- A new interventional solution from China for structural heart disease is about to be launched onto the market. Recently, TaurusOne® Transcatheter Aortic Valve Replacement System (hereinafter referred to as "TaurusOne®") developed by Peijia Medical (Suzhou) Co., Ltd., located in Suzhou Industrial Park, Jiangsu Province, was officially approved for commercialization by the National Medical Products Administration of the PRC ("NMPA") with registration number GXZZ 20213130275.Academician Gao Runlin of Fuwai Hospital Chinese Academy of Medical Sciences served as Principal Investigator for the TaurusOne® registration clinical trial completed by National Centre for Cardiovascular Disease, Fuwai Hospital, The Second Affiliated Hospital ZheJiang University School of Medicine, West China Hospital of Sichuan University, General Hospital of Northern Theater Command, the Second Affiliated Hospital of Harbin Medical University and the Second Xiangya Hospital of Central South University (in order of institution codes listed in the multi-center clinical trial protocol). The clinical trial protocol employed strict enrollment criteria and passed the pre-clinical review and got approved by the CFDA (now NMPA). One-year clinical study data for TaurusOne® definitively confirmed its safety and effectiveness as a treatment for severe aortic stenosis, with no significant difference in clinical results between the bicuspid aortic valve and tricuspid aortic valve."The NMPA registration approval of TaurusOne® is an important milestone for Peijia," said Dr. Zhang Yi, Chairman and CEO of Peijia Medical, "From now on, doctors in China will have a new product to conduct TAVR procedures, while patients suffering from aortic stenosis will have an additional solution."TaurusOne® consists of a prosthetic aortic valve, a delivery catheter and a compression loading system. The aortic valve leaflet is made of bovine pericardium and is processed with a proprietary anti-calcification technique. The stent's inflow end has an enhanced radial force design, given that China has a large proportion of patients with high aortic valve calcification or bicuspid aortic valves. A balanced waist design avoids blockage of the coronary artery while also maintaining a large orifice area. The inflow end is designed with inner and outer skirts to effectively avoid or reduce paravalvular leakage. The delivery catheter is ergonomically designed with a large handle for accurate operations; the catheter has a maximum outer diameter of 18 Fr and is divided into several segments for easier, more flexible passage and delivery.Data shows that the global market of TAVR reached USD 5 billion in 2020 and is expected to maintain a high growth rate. In China, the TAVR market is still at an early development stage, suggesting enormous potential. Explosive growth is anticipated in near future to bring the industry to RMB 5.06 billion in 2025.
The approval of TaurusOne® marks Peijia Medical's entry into the commercialization of TAVR products. With TAVR products as a cornerstone of the company's structural heart disease product line, Peijia Medical will focus on independent R&D and design to build a more complete portfolio for clinical practice and demonstrate its whole-process R&D and productive capacity in the field of structural heart disease. TaurusElite®, Peijia Medical's second-generation TAVR product, is currently in registration stage, while the company's third-generation TAVR product TaurusNXT® is in preclinical preparations. Peijia Medical's success in obtaining an "expedited" approval for TaurusOne® is largely due to the company's rigorous and solid work at the product's preliminary stages. It also shows China's regulatory authorities' encouragement and support for innovation, as well as the company's rigorous innovation and meticulousness in product development, in line with its credo:"Devotion to the Heart, Reverence for Life, and Pursuit of the Most Satisfying Clinical Products".About Peijia Medical:Peijia Medical was founded in 2012 and its headquarters are in Suzhou, Jiangsu Province, China. It was listed on the Hong Kong Stock Exchange in May 2020 (stock code 09996. HK). With "Devotion to the Heart, Reverence for Life" as its vision, Peijia Medical always puts life and safety in the first place, striving to maintain human life and health with its years of exploration in technology and its persistence in innovation. Peijia Medical's strategic layout can be summarized as the "Innovation-oriented, Simultaneous Treatment of Cardiovascular and Cerebrovascular Diseases". It is dedicated to the innovation, R&D and production of high-end medical devices for structural heart disease and cerebrovascular interventions—covering aortic valve, mitral valve, tricuspid valve, surgical accessories, and diseases related to hemorrhage, ischemia and pathways in cerebrovascular intervention. It has built a relatively comprehensive product and solutions portfolio in the field of structural heart disease and cerebrovascular interventions in China. View original content:https://www.prnewswire.com/news-releases/peijia-medicals-taurusone-transcatheter-aortic-valve-replacement-system-approved-for-commercialization-301276343.htmlSOURCE Peijia Medical